The Conversation Has Been Flipped

Decades ago, the message was total prohibition — no nuance, no information, no informed choice. Now the pendulum has swung to the opposite extreme. Ayahuasca retreats are marketed as trauma therapy. Psilocybin microdosing is sold as productivity enhancement. Ibogaine is presented as the cure for addiction. Kambo is framed as a full-body reset. And if you ask a question, you risk being told you're "not ready" or "your ego is afraid."

Neither prohibition nor uncritical enthusiasm is informed consent. Both deny you the information you need to make a real decision.

After twenty years in clinical practice, I have witnessed what happens before, during, and long after people engage with these substances in ceremonial, clinical, or recreational contexts. This page is not about whether psychedelics can produce meaningful experiences — they can. It is about what mainstream wellness culture is systematically failing to disclose.

The Dependency Pattern No One Talks About

Psychedelics are routinely described as "non-addictive" because they do not produce the same biochemical dependency as opioids or alcohol. This framing is incomplete. What psychedelics can create is a different kind of dependency — a psychological and spiritual one — that can be just as binding.

People return to ceremony again and again, chasing the breakthrough, the vision, the feeling of having cracked something open. The integration window — the period after a session where real change can be anchored — gets bypassed in favor of the next experience. The medicine becomes the process, rather than a catalyst for a process that happens in ordinary life.

Some develop a relationship with these substances that mimics every other pattern of avoidance: when life gets hard, go back in. When trauma surfaces, dose again. The ceremony becomes a refuge from the integration work that ceremony is supposed to initiate.

Psychedelic dependency does not look like opioid dependency. It often looks like someone who has done fifteen ceremonies in three years and still has not changed the relationship, the job, or the behavior pattern they went in to address. The medicine stopped working — not because it does not work, but because it was being used as a substitute for embodied change.

The Dark Shaman Problem

Traditional plant medicine traditions had protocols precisely because these substances open the psyche to states and dimensions that the ordinary waking mind does not navigate. A trained curandero spent years — sometimes decades — in apprenticeship, learning not just how to administer medicine but how to hold and protect the energetic container of a ceremony.

The global psychedelic tourism boom has produced a flood of facilitators with weekend certifications, no lineage, no training in what to do when someone dissociates, no ability to recognize a participant in a spiritual emergency, and in some cases active intent to exploit. Sexual assault in ceremony is documented and underreported. Energetic predation — taking advantage of an individual whose psychological defenses are entirely dissolved — is real. People emerge from ceremonies having been used, manipulated, or spiritually destabilized by someone operating as a healer.

Even within traditional lineages, not all practitioners are benevolent. The concept of the "dark shaman" — one who uses knowledge of the plant and the ceremonial space to harm rather than heal — is not a metaphor in the communities where these traditions originate. It is a documented reality.

When a substance removes your ordinary cognitive gatekeeping, you are entirely dependent on the integrity of the person holding the space. You cannot vet someone properly while you are under the influence. This is not a solvable problem with better screening — it is an inherent vulnerability of the state.

Doors You May Not Be Able to Close

Strong psychedelic experiences can permanently alter perception — not always in the direction of healing. HPPD (Hallucinogen Persisting Perception Disorder) is classified and documented, but it represents only the most measurable end of a larger spectrum. Some people emerge from psychedelic experiences with persistent altered states, an inability to return to ordinary baseline reality, new fear responses, or what is sometimes called "ontological shock" — a fundamental disruption in how reality is experienced that does not resolve with time.

These outcomes are not rare enough to be treated as edge cases in genuine informed consent conversations. And yet they are routinely omitted from promotional materials, retreat websites, and facilitator intake processes.

Certain individuals are significantly more vulnerable: those with personal or family history of psychosis, schizophrenia, or bipolar disorder; those with active trauma responses without a stable integration container; those on medications that interact; those in states of physical depletion, adrenal exhaustion, or low redox charge. For these individuals, the risk is not theoretical.

The Violation of Mind, Body, and Spirit

The psyche, like the body, has a protective boundary. Ordinary waking consciousness maintains that boundary. Psychedelics dissolve it — sometimes partially, sometimes entirely. In that dissolved state, experiences can enter that leave permanent marks: encounters with entities, reliving of trauma without containment, loss of self-boundaries that does not fully reconstitute. The person who returns is not always the person who went in.

When this happens without full informed consent, without adequate preparation, and without skilled support, it is a violation of the deepest kind — of mind, body, and spirit simultaneously. The fact that it was marketed as healing — or that the person wanted healing — does not change what it was.

This is not theoretical. It is the clinical reality I have encountered with people who came to me after ceremony. Rebuilding what was fractured in these experiences takes years, not weeks.

The Microdosing Push — and What It Leaves Out

Microdosing — taking a sub-perceptual fraction of a psychedelic dose (typically 1/10th to 1/20th of a full dose) — has been rebranded as a productivity tool, a creativity enhancer, and an antidepressant alternative. Tech culture adopted it. Media normalized it. Podcasts celebrate it. And the people promoting it are almost never disclosing what the research actually shows, what the risks are, or what "sub-perceptual" actually means when the source is an illegal supply chain with no standardization.

There is no standardized dose. The substance being sold as psilocybin may contain other compounds, may be a different species entirely, or may be significantly more or less potent than assumed. This is not a minor variable — the difference between a micro-dose and a dose that produces a full perceptual experience can be a fraction of a gram. People who believed they were microdosing have had full psychedelic experiences at work, while driving, and while parenting.

What the marketing says

Sub-perceptual doses improve mood, focus, and creativity with no psychedelic effect. Non-addictive. Neuroplasticity-enhancing. Depression alternative.

What is not disclosed

No long-term safety data. Illegal supply, no dose standardization. Serotonin receptor desensitization with chronic use. Anxiety amplification documented. HPPD risk at low doses. Tolerance forces escalation. Psychological dependency pattern identical to other avoidance cycles.

The serotonin receptor desensitization concern is not theoretical. Chronic activation of 5-HT2A receptors — even at low doses — triggers receptor downregulation over time. This is the mechanism behind SSRI tolerance. With microdosing, the result is often emotional blunting between doses, increasing difficulty feeling neutral or regulated without the substance, and a mood that cycles with the dosing schedule rather than improving independent of it. People report that stopping is harder than expected. That is dependency — it simply does not look like the cultural picture of addiction.

Ketamine Clinics — The Legal Psychedelic No One Is Questioning

Ketamine is a dissociative anesthetic — Schedule III, legally available, and since 2019, FDA-approved in nasal spray form (Spravato/esketamine) for treatment-resistant depression. IV ketamine infusion clinics have proliferated across the US. They are being marketed aggressively — directly to people who have failed antidepressants, who are in crisis, who are desperate. Celebrity culture has accelerated this: Elon Musk has openly discussed using ketamine for depression. Matthew Perry died of acute ketamine effects while reportedly receiving ketamine treatment. The demand has never been higher.

The clinical evidence for ketamine in treatment-resistant depression is real. So are the risks that clinics are not leading with. Ketamine is the same molecule whether it is administered in a clinical setting or used recreationally as Special K. The route and dose differ; the pharmacology does not. And what chronic use does to the bladder — ketamine cystitis — is one of the most devastating and underreported risks in medicine right now.

Ketamine is concentrated and excreted through the urinary tract. Chronic exposure causes progressive inflammation, scarring, and fibrosis of the bladder wall — a condition called ketamine-induced uropathy or ketamine cystitis. Symptoms include severe pelvic pain, frequency, urgency, and incontinence. In serious cases, bladder capacity shrinks to the point of requiring cystectomy — surgical removal of the bladder. This is documented in recreational users and is now emerging in clinical treatment populations receiving repeated infusions. Most ketamine clinics do not mention it.

The dissociative state itself is also not disclosed as clearly as it should be. During a ketamine infusion, you are in a K-hole — a profound dissociative state in which you may be incapable of signaling distress, expressing consent, or registering what is happening around you. You are entirely dependent on the integrity and vigilance of whoever is in the room. In a clinic where profit depends on throughput and sessions are stacked, that means a nurse or technician, checking in periodically. The person holding the space during the most psychologically open state you will be in is, in most clinics, not a trained trauma therapist. They are administering an anesthetic and monitoring vital signs.

Integration support — the follow-up work that research consistently identifies as determinative of outcomes — is often absent, minimal, or an expensive add-on. The business model sells infusions. The six-session starter package costs $3,000–$6,000 out of pocket in most markets. Insurance coverage is inconsistent and often denied. People in the most vulnerable psychiatric states, who have already failed standard treatment, are spending money they may not have on a treatment that requires ongoing infusions to maintain effect in many patients, with no clear exit protocol and risks that were never fully explained.

Who Should Not Engage With These Substances

Psychiatric History

Personal or first-degree family history of schizophrenia, bipolar I, schizoaffective disorder, or psychosis is a significant contraindication — particularly for high-dose or long-duration compounds.

Active Trauma Without Container

Unprocessed trauma without an established therapeutic relationship and integration plan significantly increases the risk of re-traumatization rather than resolution.

Medication Interactions

SSRIs, SNRIs, MAOIs, lithium, tramadol, and many other medications have documented — and sometimes life-threatening — interactions. See the Drug Interactions tab.

Cardiovascular Compromise

Ibogaine carries documented risk of fatal cardiac arrhythmia. Kambo triggers intense cardiovascular and autonomic stress. Any existing cardiac condition requires extreme caution.

Physical Depletion / Low Redox

A body that is chronically inflamed, minerally depleted, or operating on low cellular charge does not have the physiological reserves to process an intense psychedelic experience safely.

Pregnancy

No established safety data exists for any of these substances in pregnancy. Profound autonomic activation, purging, and cardiovascular stress are all contraindicated.

If You Choose to Engage Anyway

This is not a position of prohibition. It is a position of informed choice. If after understanding the full picture you choose to explore, here is what responsible engagement looks like:

• ✦ Vet the facilitator rigorously. Understand their lineage, training, years of experience, safety protocols, and what they do when something goes wrong. Ask for references from people who have worked with them over years — not weeks.
• ✦ Never go alone. Someone you trust — sober, grounded, not a participant — should be physically reachable throughout.
• ✦ Full medication disclosure. Provide your complete medication and supplement list. If the facilitator is not asking for this, that is already a red flag.
• ✦ Have a practitioner lined up for integration. The work happens in the weeks after, not during the session. Without this, you are leaving the most important part undone.
• ✦ Physical preparation matters. Clean nutrition, adequate sleep, mineral status, and low toxic load in the weeks prior are not optional. A depleted body is not equipped to process a strong experience.
• ✦ Start lower than you think you need. There is no emergency mechanism in the middle of a high-dose experience. You can always go deeper — you cannot go back.
• ✦ Long intervals between sessions. Six months to a year minimum between significant experiences. Real integration takes that long. Returning sooner is usually avoidance.
• ✦ Know the exit. Have a plan — in writing — for what happens if you experience persistent altered states or psychological destabilization after the session. Know who you call. Know where you go.

After twenty years of clinical practice I have worked with people before and after psychedelic experiences. I have helped rebuild people whose boundaries were violated in ceremony, supported those who could not return to baseline for months, and witnessed both genuine breakthrough and genuine harm. My position is not that these substances are never relevant — it is that the level of informed consent currently offered in the wellness space does not meet any reasonable ethical standard. You deserve the full picture. — Allie Johnson, DNM